Human medicines European public assessment report (EPAR): Emgality, galcanezumab, Date of authorisation: 14/11/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 6, Status: Authorised

Annex to 27-30 January 2025 CHMP Minutes

Minutes of the CHMP meeting 27-30 January 2025

Human medicines European public assessment report (EPAR): Ibuprofen Gen.Orph, ibuprofen, Date of authorisation: 16/02/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Privigen, human normal immunoglobulin (IVIg), Date of authorisation: 24/04/2008, Revision: 32, Status: Authorised

Ixchiq

Strengthening evidence generation in the EU, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 10 June 2025, 14:00 (CEST) to 10 June 2025, 15:00 (CEST)